CASC2: A Potential Drug Target for Cancer (G255082)

Target Name: CASC2

NCBI ID: G255082

CASC2

Other Name(s): MGC117219 | CASC2 variant 1 | Cancer susceptibility 2, transcript variant 1 | cancer susceptibility 2 | C10orf5

CASC2: A Potential Drug Target for Cancer

Cancer-associated protein-2 (CASC2) is a protein that is expressed in various types of cancer, including breast, lung, and ovarian cancer. It is a member of the protein tyrosine kinase family and is involved in cell signaling pathways, including the TGF-β pathway.CASC2 has also been shown to play a role in cancer cell survival and has been identified as a potential drug target in cancer treatment.

CASC2 is a 21-kDa protein that is expressed in various types of cancer, including breast, lung, and ovarian cancer. It is a member of the protein tyrosine kinase family and is involved in cell signaling pathways, including the TGF-β pathway. The TGF-β pathway is a well-established pathway that is involved in cell signaling and is involved in the development and maintenance of tissues, including cancer.

CASC2 has been shown to play a role in cancer cell survival by regulating cell apoptosis, which is the process by which cells undergo programmed cell death. Studies have shown that CASC2 can inhibit theApoptosis-associated protein (Bcl-2) gene, which encodes a protein that can induce cell apoptosis. This means that when cells are exposed to CASC2, they are less likely to undergo apoptosis.

CASC2 has also been shown to play a role in cancer cell proliferation by regulating cell cycle progression. The cell cycle is the process by which cells grow and divide, and it is a critical process for cancer growth. Studies have shown that CASC2 can inhibit the cyclin D1 gene, which encodes a protein that is involved in cell cycle progression. This means that when cells are exposed to CASC2, they are less likely to enter the cell cycle and continue to divide.

CASC2 has also been shown to play a role in cancer cell migration by regulating the migration of cells. Cancer cells are able to migrate from the primary tumor to other parts of the body, where they can establish new tumors. Studies have shown that CASC2 can inhibit the migration of cells by regulating the activity of the protein Integrin. This means that when cells are exposed to CASC2, they are less likely to migrate.

In addition to its role in cancer cell survival and proliferation, CASC2 has also been shown to play a role in cancer cell angiogenesis. Angiogenesis is the process by which new blood vessels are formed in the body, and it is a critical process for cancer growth Studies have shown that CASC2 can inhibit the angiogenesis of cells by regulating the activity of the protein PDGFR-尾. This means that when cells are exposed to CASC2, they are less likely to form new blood vessels.

CASC2 has also been shown to play a role in cancer cell immune surveillance. Cancer cells are able to evade the immune system and continue to divide and grow, despite the efforts of the immune system. Studies have shown that CASC2 can inhibit the immune surveillance of cells by regulating the activity of the protein PD-L1. This means that when cells are exposed to CASC2, they are less likely to be able to evade the immune system.

In conclusion, CASC2 is a protein that is involved in various aspects of cancer cell signaling pathways, including cell apoptosis, cell cycle progression, cancer cell migration, and cancer cell angiogenesis. It has been shown to play a role in cancer cell survival and proliferation , as well as in cancer cell immune surveillance. As a result, CASC2 is a potential drug target for cancer treatment. Further research is needed to fully understand the role of CASC2 in cancer and to develop effective treatments.

Protein Name: Cancer Susceptibility 2

Functions: May act as a potential tumor suppressor

The "CASC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets